Navigation Links
Vanda Pharmaceuticals Reports Second Quarter 2009 Results
Date:8/10/2009

74,549 1,306,762 Net loss $(12,392,101) $(13,494,882) $(18,896,088) $(32,691,011) ============ ============ ============ ============ Basic and diluted net loss per share attributable to common stockholders $(0.46) $(0.51) $(0.71) $(1.23) ====== ====== ====== ====== Shares used in calculation of basic and diluted net loss per share attributable to common stockholders 26,900,841 26,649,439 26,777,159 26,648,892 ========== ========== ========== ========== VANDA PHARMACEUTICALS INC. (A Development Stage Enterprise) CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) June 30, 2009 December 31, 2008 ------------- ----------------- ASSETS Current assets: Cash and cash equivalents $24,014,203 $39,079,304 Marketable securities 5,008,623 7,378,798 Prepaid expenses, deposits and other current assets 1,129,194 1,287,400 Inventory 1,272,240 - --------- --------- Total current assets 31,424,260 47,745,502 Property and equipment, net 1,518,442 1,758,111 Restricted cash 430,230 430,230 Intangible asset, net 11,770,648 - ---------- ---------- Total assets $45,143,580 $49,933,843 ==
'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
8. Vanda Pharmaceuticals Reports First Quarter 2009 Results
9. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
10. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... August 20, 2014 One of ... medicine is an inadequate vascular supply. Nutrient and ... decellularized tissues is critical for successful regeneration and ... to mitigate deficiencies in vascularization and promote angiogenesis ... bioactivity, optimizing scaffold design and architecture, and enhancing ...
(Date:8/19/2014)... Cellgen Diagnostics today ... fund a corporate lab for its genetic-based medical ... is a critical component in the move from ... implementation of personalized medicine – a more predictive, ... Indiegogo contributions will support Cellgen’s intent to develop ...
(Date:8/19/2014)... 19, 2014 Research and ... the "Spectroscopy Equipment and Accessories - ... their offering. This report ... and Accessories in US$ Thousands by the ... Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) ...
(Date:8/19/2014)... Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" ... reported results of its Oral Amphotericin B (Oral ... The study, conducted by ImmuneCarta®, the immune monitoring ... effectiveness of Oral Amp B in reactivating ... individuals despite intensive treatment with antiretroviral therapy. ...
Breaking Biology Technology:Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3
... to present at 2008 BIO CEO & Investor conference at ... New York on Tuesday, February 12 at 1:15 PM (Eastern), ... -- James A. Bianco, M.D., President and CEO of Cell,Therapeutics, ... overview of,the Company,s sales and marketing strategy intended to grow ...
... eResearchTechnology,Inc. (eRT), (Nasdaq: ERES ), ... and interpretation services including,expert consultation and a ... capture and electronic patient reported outcomes,solutions), announced ... fourth quarter,results for the period ended December ...
... CHICAGO, Feb. 11 Advanced Life Sciences,Holdings, Inc. ... in the,discovery, development and commercialization of novel drugs ... diseases today,announced that it will host a conference ... and full-year financial results on Tuesday,February 19 at ...
Cached Biology Technology:Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 2Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 3Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 4Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 5eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008 2Advanced Life Sciences To Host 2008 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 2Advanced Life Sciences To Host 2008 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 3
(Date:8/19/2014)... German . , , ... of plants can switch off individual genes and study ... Planck Institute for Plant Breeding Research in Cologne and ... different approach. They identify small molecules that block specific ... prevent the downstream reactions. In their search for these ...
(Date:8/19/2014)... young have bigger brains than counterparts that don,t care ... study. , Stickleback fish are well known in the ... the species, rather than the female, cares for offspring. ... researchers wanted to find out if the difference in ... , In the study, published recently in Ecology ...
(Date:8/18/2014)... Ariz. Half of the Earth,s land mass is ... yet they are being transformed at an alarming rate. ... in and taking over, leading to a loss of ... ability of ecosystems to produce food specifically meat. ... Life Sciences led an investigation that quantified this loss ...
Breaking Biology News(10 mins):Researchers block plant hormone 2Researchers block plant hormone 3Trees and shrubs invading critical grasslands, diminish cattle production 2Trees and shrubs invading critical grasslands, diminish cattle production 3
... N.Y. Proteins are critically important to life and the ... in nature, and there is much we still don,t know ... the stability of enzymes, a particular type of protein that ... natural environment in the cell or body, enzymes can quickly ...
... that nanoparticles, which are now present in everything from ... irreparably damaging effects on soil systems and the environment. ... every year, including silver nanoparticles which are popular as ... Department of Biology. "We started to wonder what the ...
... (April 6, 2011) -- A new drug delivery device ... Peter Rentzepis promises to unlock the potential of photosensitive ... as well. Photosensitive chemicals are molecules that ... These radicals are very active chemically, and can rip ...
Cached Biology News:Nano fit-ness: Helping enzymes stay active and keep in shape 2Common nanoparticles found to be highly toxic to Arctic ecosystem 2New device promises safer way to deliver powerful drugs 2
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... C-terminus of Human MSY2/YBOX2. (Note: ... (Peptide available as ...
... Immunogen: Peptide corresponding ... human, mouse, and rat phospho-FAK (Ser843) ... NM_153831 Quality ... Molecular Weight: ...
Biology Products: